Chatbot coach for cancer patients: a new way to tackle drug side effects
NCT ID NCT07310589
First seen Jan 06, 2026 · Last updated May 12, 2026 · Updated 18 times
Summary
This study tests a visual interactive chatbot on the LINE app to help people with advanced lung cancer manage side effects from targeted therapy (EGFR-TKIs). About 178 participants will either get usual care or also access the chatbot, which provides tips and tracking for symptoms. The goal is to see if the chatbot improves patients' ability to care for themselves and their quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.